Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy

Antiviral Research

Volumn 126, Issue , 2016, Pages 35-42

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Murata, Masayuki ^a   Hayashi, Takeo ^a   Shimizu, Motohiro ^a   Mukae, Haru ^a   Toyoda, Kazuhiro ^a   Hotta, Taeko ^a   Uchiumi, Takeshi ^a   Hayashi, Jun ^b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b Hara Doi Hospital   (Japan)

Author keywords

Hepatitis C virus; Pegylated interferon; Protease inhibitor; Real time PCR; Simeprevir

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; NS4B PROTEIN, FLAVIVIRUS; PROTEINASE INHIBITOR; VIRAL PROTEIN;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS KINETICS; HUMAN; JAPANESE (PEOPLE); LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOWER LIMIT OF DETECTION; LOWER LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; POLYMERASE CHAIN REACTION SYSTEM; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SENSITIVITY ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84957866213     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.12.001     Document Type: Article

References (24)

1. S. Chevaliez, M. Bouvier-Alias, and J.M. Pawlotsky Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification J. Clin. Microbiol. 47 2009 1726 1732
2. P. Ferenci, H. Laferl, T.M. Scherzer, M. Gschwantler, A. Maieron, H. Brunner, R. Stauber, M. Bischof, B. Bauer, C. Datz, K. Löschenberger, E. Formann, K. Staufer, and P. Steindl-Munda Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451 458
3. B. Fevery, S. Susser, O. Lenz, G. Cloherty, D. Perner, G. Picchio, and C. Sarrazin HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy Antivir. Ther. 19 2014 559 567
4. N. Furusyo, E. Ogawa, M. Nakamuta, E. Kajiwara, H. Nomura, K. Dohmen, K. Takahashi, T. Satoh, K. Azuma, A. Kawano, Y. Tanabe, K. Kotoh, S. Shimoda, and J. Hayashi Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C J. Hepatol. 59 2013 205 212
5. P.R. Harrington, W. Zeng, and L.K. Naeger Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment Hepatology 55 2012 1048 1057
6. H. Ikezaki, N. Furusyo, T. Ihara, T. Hayashi, E. Ogawa, K. Toyoda, H. Taniai, M. Kainuma, M. Murata, and J. Hayashi Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C J. Infect. Chemother. 17 2011 737 743
7. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, and S. Zeuzem Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
8. D.M. Jensen, T.R. Morgan, P. Marcellin, P.J. Pockros, K.R. Reddy, S.J. Hadziyannis, P. Ferenci, A.M. Ackrill, and B. Willems Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960
9. H.H. Kessler, B.R. Cobb, H. Wedemeyer, B. Maasoumy, V. Michel-Treil, L. Ceccherini-Nelli, B. Bremer, M. Hübner, A. Helander, H. Khiri, G. Heilek, C.O. Simon, K. Luk, S. Aslam, and P. Halfon Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: the ExPECT study J. Clin. Virol. 67 2015 67 72
10. K.V. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M.N. Davis, M. DeMicco, D.E. Bernstein, N. Afdhal, J.M. Vierling, S.C. Gordon, J.K. Anderson, R.H. Hyland, H. Dvory-Sobol, D. An, R.G. Hindes, E. Albanis, W.T. Symonds, M.M. Berrey, D.R. Nelson, and I.M. Jacobson Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
11. B. Maasoumy, B. Cobb, B. Bremer, K. Luk, P. Halfon, S. Aslam, M.P. Manns, M. Cornberg, and R.H. Wedemeye Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir Aliment. Pharmacol. Ther. 39 2014 85 92
12. B. Maasoumy, B. Hunyady, V. Calvaruso, M. Makara, J. Vermehren, A. Haragh, S. Susser, B. Bremer, G. Cloherty, M.P. Manns, A. Craxì, H. Wedemeyer, and C. Sarrazin Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis PLoS One 9 2014 e110857
13. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, G.L. Ricci, V. Carretta, F. Vinelli, G. Scotto, G. Montalto, M. Romano, G. Cristofaro, L. Mottola, F. Spirito, and A. Andriulli Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50
14. M. Manns, P. Marcellin, F. Poordad, E.S. de Araujo, M. Buti, Y. Horsmans, E. Janczewska, F. Villamil, J. Scott, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, G. De La Rosa, R. Kalmeijer, R. Sinha, and M. Beumont-Mauviel Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
15. E. Ogawa, N. Furusyo, K. Toyoda, H. Takeoka, S. Maeda, and J. Hayashi The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin Antivir. Res. 83 2009 127 134
16. E. Ogawa, N. Furusyo, M. Nakamuta, E. Kajiwara, H. Nomura, K. Dohmen, K. Takahashi, T. Satoh, K. Azuma, A. Kawano, Y. Tanabe, K. Kotoh, S. Shimoda, and J. Hayashi Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study Aliment. Pharmacol. Ther. 38 2013 1076 1085
17. E. Ogawa, N. Furusyo, M. Murata, K. Toyoda, K. Eiraku, M. Shimizu, Y. Harada, F. Mitsumoto, K. Takayama, K. Okada, M. Kainuma, and J. Hayashi Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays Antivir. Res. 99 2013 119 124
18. E. Ogawa, N. Furusyo, M. Shimizu, T. Ihara, T. Hayashi, Y. Harada, K. Toyoda, M. Murata, and J. Hayashi Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C Antivir. Ther. 20 2015 185 192
19. E. Ogawa, N. Furusyo, E. Kajiwara, H. Nomura, A. Kawano, K. Takahashi, K. Dohmen, T. Satoh, K. Azuma, M. Nakamuta, T. Koyanagi, K. Kotoh, S. Shimoda, and J. Hayashi Comparative safety study on severe anemia by simeprevir- versus telaprevir-based triple therapy for chronic hepatitis C J. Gastroenterol. Hepatol. 30 2015 1309 1316
20. E. Ogawa, N. Furusyo, E. Kajiwara, H. Nomura, A. Kawano, K. Takahashi, K. Dohmen, T. Satoh, K. Azuma, M. Nakamuta, T. Koyanagi, K. Kotoh, S. Shimoda, and J. Hayashi Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection J. Gastroenterol. Hepatol. 30 2015 1759 1767
21. C. Sarrazin, M.L. Shiffman, S.J. Hadziyannis, A. Lin, G. Colucci, H. Ishida, and S. Zeuzem Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy J. Hepatol. 52 2010 832 838
22. N. Taylor, E. Haschke-Becher, R. Greil, M. Strasser, and H. Oberkofler Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections Antivir. Ther. 19 2014 449 454
23. J. Vermehren, A. Aghemo, K. Falconer, S. Susser, G. Lunghi, S. Zeuzem, M. Colombo, O. Weiland, and C. Sarrazin Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection J. Hepatol. 60 2014 913 919
24. H. Zitzer, G. Heilek, K. Truchon, S. Susser, J. Vermehren, D. Sizmann, B. Cobb, and C. Sarrazin Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design J. Clin. Microbiol. 51 2013 571 577